Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure
Not Applicable
Recruiting
- Conditions
- Dexmedetomidine
- Interventions
- Drug: Dexmedetomidine with Mannitol
- Registration Number
- NCT07064720
- Lead Sponsor
- Cairo University
- Brief Summary
Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
ASA I-II Patients scheduled for elective robot-assisted laparoscopic prostatectomy
Exclusion Criteria
-
• ASA physical status > II
- Cardiac patients
- Cerebrovascular disease
- Glaucoma
- Hepatic failure
- Renal failure
- History of anaphylactic reaction to dexmedetomidine or mannitol
- Hemodynamic instability
- Cannot measure ONSD for example due to ophthalmological problems.
- Any cause of preoperative increase in ICP for example intracranial space occupying lesions.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group (D) Dexmedetomidine with Mannitol Dexmedetomidine with Mannitol Group (M) Mannitol (20%) Mannitol only
- Primary Outcome Measures
Name Time Method optic nerve sheath diameter 90 minutes
- Secondary Outcome Measures
Name Time Method Postoperative cardiac complications 24 hours Postoperative neurologic complications 24 HOURS Duration of hospital stay 30 days
Trial Locations
- Locations (1)
facility of medicine Cairo university
🇪🇬Cairo, Egypt
facility of medicine Cairo university🇪🇬Cairo, EgyptAmr WahdanContact01001422499amrwahdan@kasraliny.edu.egHeba IsmailContact01220807670Samar Hassan KoshekSub Investigator